All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
On November 2, 2022, it was announced that the European Commission had granted approval to zanubrutinib, a Bruton’s tyrosine kinase inhibitor, for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior line of anti-CD20-based therapy.1
The approval follows a positive opinion granted by the European Medicine Agency’s Committee for Medicinal Products for Human Use in September of this year and is based on key results of the phase II MAGNOLIA trial (NCT03846427). In the trial, zanubrutinib demonstrated a high overall response rate and acceptable safety in marginal zone lymphoma, consistent with its established profile.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Phase II MAGNOLIA trial: Efficacy and safety of zanubrutinib in marginal zone lymphoma
Bruton’s tyrosine kinase (BTK) inhibitors provide a highly selective mechanism of action in marginal zone lymphoma (MZL), targeting B-cell receptor signaling...
Novel targeted therapies for R/R marginal zone lymphoma
It has been challenging to define an optimal therapeutic approach for relapsed patients with marginal zone lymphoma (MZL) due to disease heterogeneity, especially in the advanced, refractory...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox